EUCTR2016-004376-21-IT
Active, not recruiting
Phase 1
Investigation of 68GaPSMA PET/CT as an imaging biomarker in solid tumors - BASKET GA-PSMA
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS0 sites400 target enrollmentSeptember 20, 2018
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- advanced/metastatic solid tumors
- Sponsor
- ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
- Enrollment
- 400
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients with mCRPC or advanced/metastatic solid tumors;
- •2\.Relapse or progression disease on CT scan and / or MR;
- •3\.Age \= 18 years;
- •4\.Written informed consent
- •5\. ECOG performance status \=2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 180
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •1\.Pregnancy / Nursing;
- •2\.History of allergic reactions attributed to compounds of similar chemical or biologic composition to 68Ga\-PSMA or other agents used in the study.
- •3\. inability to remain still for the entire duration of the exam
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
68Ga-PSMA HBED-PET/CT in the evaluation of the biochemical relapse in patients with a history of prostate cancer radically treated.prostate cancerMedDRA version: 20.0Level: LLTClassification code 10001186Term: Adenocarcinoma of prostateSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-003397-33-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS67
Active, not recruiting
Phase 1
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2016-000842-79-BEInstitut Jules Bordet75
Recruiting
Not Applicable
68Gallium-Prostate Specific Membrane Antigen (68Ga-PSMA) Positron Emission Tomography (PET) as a potential Imaging biomarker post tyrosine kinase inhibition of metastatic clear cell Renal cell Carcinoma (PIRC) – a pilot studyACTRN12621000651886Olivia Newton-John Cancer Research Institute20
Active, not recruiting
Phase 1
Evaluation of 68Ga-PSMA PET-CT in the initial extension assessment of advanced renal cell carcinomaa prospective, multicenter, open studyrenal cell cancer (RCC)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-003760-47-FRAssistance Publique Hôpitaux de Marseille44
Completed
Not Applicable
68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinomaNL-OMON44299Radboud Universitair Medisch Centrum25